Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients Treated with Celladon’s Genetically Targeted Enzyme Replacement Therapy MYDICAR® Date: May 30, 2010 Client: Celladon Corp. Summary: BERLIN, May 30, 2010 – Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.
		Data Presented at EuroPCR 2010 Demonstrate Effectiveness of OrbusNeich's Genous™ Bio-engineered R stent™ in Diabetic Patients Date: May 26, 2010 Client: OrbusNeich Summary: PARIS, May 26, 2010 – OrbusNeich today announced that 12-month follow-up data from a subset analysis of the global e-HEALING registry demonstrate that the company’s Genous Bio-engineered R stent is effective in diabetic patients.
		Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom Date: May 26, 2010 Client: Amira Pharmaceuticals, Inc. Summary: San Diego, CA - May 26, 2010 -- Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, “HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS,” which includes coverage of Amira’s AM461 DP2 receptor antagonist.
		Cempra Pharmaceutical's Cem-101 Demonstrates Potent Anti-Inflammatory Activity, Compared To Other Macrolide Antibiotics, In An Inflammation Cell Model At The American Thoracic Society 2010 International Conference Date: May 18, 2010 Client: Cempra Pharmaceuticals Summary: Chapel Hill, N.C., May 18, 2010 - Cempra Pharmaceuticals today announced the results from two poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, at the American Thoracic Society 2010 International Conference, May 14 to 19, 2010, in New Orleans. Both presentations are scheduled for 8:15 a.m. to 4 p.m. CDT on Tuesday, May 18.
		Alder, Bristol Arthritis Drug Shows “Outstanding” Results in Trial, Lead Researcher Says Date: May 17, 2010 Client: Alder Biopharmaceuticals Summary: Six months after Bristol-Myers Squibb (NYSE: BMY) wrote a big check to Bothell, WA-based Alder Biopharmaceuticals, we can see what some of the fuss is about.
		Data on the Anti-inflammatory Activity of Cempra Pharmaceutical's CEM-101 Will be Presented at the American Thoracic Society 2010 International Conference Date: May 13, 2010 Client: Cempra Pharmaceuticals Summary: CHAPEL HILL, N.C., May 13 /PRNewswire/ -- Cempra Pharmaceuticals today announced the schedule of poster presentations on its next-generation macrolide, CEM-101, at the American Thoracic Society (ATS) 2010 International Conference in New Orleans, Louisiana, on May 14 to 19, 2010.
		Alder Seeks to Treat Cancer in a Radical Way, Fighting Inflammation, Not Tumors Date: May 13, 2010 Client: Alder Biopharmaceuticals Summary: There are a lot of radical ideas for treating cancer, and most are pure bunk. But now one of Seattle’s most promising biotech startups, Alder Biopharmaceuticals, says it has the first hard evidence to support a concept that would have gotten them laughed out of the room by most cancer physicians a year ago.
		Ardea Biosciences to Present Additional Data on Gout Program at the Annual European Congress of Rheumatology Date: May 13, 2010 Client: Ardea Biosciences Summary: SAN DIEGO, May 13, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it will present additional data from its completed Phase 2a and Phase 2b monotherapy studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy on June 18th and 19th. The Company will also present additional RDEA594 and allopurinol combination data from its completed Phase 2a study, RDEA594 and febuxostat (Uloric(R), Takeda Pharmaceutical Company Limited; Adenuric(R), Ipsen and Menarini) combination data from its completed Phase 1 study, as well as data on its next-generation URAT1 inhibitor program.
		Cempra Pharmaceuticals Names Mark W. Hahn as Executive Vice President and Chief Financial Officer Date: May 6, 2010 Client: Cempra Pharmaceuticals Summary: CHAPEL HILL, N.C, May 6, 2010 - Cempra Pharmaceuticals Inc. today announced the appointment of Mark W. Hahn as executive vice president and chief financial officer.
		Anti-Fibrotic Data from Amira Pharmaceuticals’ LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology Date: May 6, 2010 Client: Amira Pharmaceuticals Summary: San Diego, CA - May 6, 2010 -- Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.
		Cohera sees favorable results with TissuGlu in clinical study Date: May 6, 2010 Client: Cohera Medical, Inc.® Summary: In just four years Cohera Medical's (Pittsburgh) TissuGlu application has gone from an adhesive with untapped potential, to a product that shows promise in clinical studies as being a safe and effective means of facilitating wound drainage. The company recently reported that TissuGlu saw preliminary favorable results in a prospective, open-label, randomized study involving 40 patients at three sites in Germany.
		Singapore's S*BIO Expands Collaboration With Onyx On JAK2 Inhibitors Date: May 5, 2010 Client: S*BIO Summary: PERTH, Australia - Singapore-based S*BIO and U.S.-based Onyx Pharmaceuticals are expanding their development collaboration to include additional indications for S*BIO's novel JAK2 inhibitors, the companies announced May 4.
		Top-Line Human Clinical Study Results Demonstrate Safety and Preliminary Effectiveness of Cohera Medical’s TissuGlu® Date: May 5, 2010 Client: Cohera Medical, Inc. Summary: PITTSBURGH, May 5, 2010 - Cohera Medical, Inc.® today announced that top-line clinical study results demonstrate the safety and preliminary effectiveness of the company's lead surgical adhesive product, TissuGlu®.
		gMed to Support the Digestive Health Outcomes Registry in Partnership With AGA and MedAssurant Date: May 4, 2010 Client: MedAssurant Inc. Summary: BETHESDA, Md., and BOWIE, Md. – May 04, 2010 – The American Gastroenterological Association (AGA), the leading association representing clinicians and researchers who specialize in the digestive tract, and MedAssurant Inc., a leading provider of data-driven healthcare solutions, announced today that gMED, the market leader in electronic health records (EHRs) for gastroenterologists, has agreed to configure its EHR solutions to enable seamless data transmission to the AGA Digestive Health Outcomes Registry TM. The registry, a collaboration between MedAssurant and the AGA, is the first in a series that will address outcomes for patients with digestive disease.
		Cempra Announces Positive Results From Its Phase 2 Clinical Trial Of TakstaTM (Sodium Fusidate) In Patients With Acute Bacterial Skin And Skin Structure Infections (Absssi) Date: May 4, 2010 Client: Cempra Pharmaceuticals Summary: CHAPEL HILL, N.C., May 4, 2010 - Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTATM (CEM-102, sodium fusidate), the company's oral, anti-methicillinresistant Staphylococcus aureus (MRSA) antibiotic. The study demonstrated efficacy comparable to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI) indicating that TAKSTA will have a high probability of demonstrating non-inferiority vs. linezolid in pivotal Phase 3 trials. The TAKSTA loading dose regimen was well tolerated.